Cell/Gene Tx channel feed

Ness Berming­ham looks to lead the wave of RNA edit­ing at new At­las up­start Ko­r­ro Bio

6 years ago
Startups

Ear­ly func­tion­al da­ta on limb gir­dle pa­tients buoy ex­pec­ta­tions for Sarep­ta's gene ther­a­py

6 years ago
R&D

Re­gen­eron dou­bles down on part­ner Adicet's gam­ma delta T cell tech in $80M fi­nanc­ing

6 years ago
Financing

San Fran­cis­co biotech has its heart in heart fail­ure — and $92M in the bank

6 years ago
Startups

ARC-T? Al­ter­na­tive CAR-T start­up bags $85M for clin­i­cal quest to redi­rect 'blind hunter' T cells

6 years ago
Startups

Neoanti­gen play­er PACT Phar­ma woos Tim Moore from Kite to run tech­ni­cal ops

6 years ago
People

The time is now: John Cox as­sumes CEO post at Flag­ship-backed Torque, steer­ing cell ther­a­py to clin­i­cal tri­als

6 years ago
People

Reg­u­la­tors throw up an­oth­er hur­dle to Roche’s $4.3B Spark ac­qui­si­tion as ques­tions per­co­late over he­mo­phil­ia mar­ket dom­i­na­tion

6 years ago
Deals

No­var­tis ac­cus­es 2 AveX­is founders of al­ter­ing da­ta, stonewalling probe — but ex-CSO blasts back

6 years ago
Pharma
FDA+

Zol­gens­ma did­n't cause an in­fant death, AveX­is ex­ecs say as they spot­light long-term da­ta

6 years ago
R&D
Pharma

'Dis­con­nect the bas­tard­s' — one biotech's plan to break can­cer cell­s' uni­fied de­fens­es

6 years ago
R&D

Ear­ly snap­shot of Ad­verum's eye gene ther­a­py sparks con­cern about vi­sion loss

6 years ago
R&D

Ital­ian gene ther­a­py play­er draws new in­vestor from Chi­na for its an­swer to CAR-T re­laps­es

6 years ago
Financing

A new play­er jumps in­to the heat­ed race for a sick­le cell cure, with help from Google's GV

6 years ago
R&D

Lon­don's 4BIO Cap­i­tal un­veils first close of $150M fund ded­i­cat­ed to ad­vanced ther­a­pies

6 years ago
Financing

Plot­ting clin­i­cal en­try, James Wilson's gene ther­a­py start­up brings in bil­lion­aire for $110M Se­ries B

6 years ago
Financing

Nkar­ta maps out clin­i­cal, man­u­fac­tur­ing plans for CAR-NK fol­low­ing $114M round led by Sam­sara

6 years ago
Financing
Startups

Syn­cona dives deep in­to dry AMD R&D, up­ping Gy­ro­scope bet to $100M

6 years ago
Financing
R&D

Im­mat­ics scores $75M up­front in TCR deal with Cel­gene as in­ter­est in tech bur­geons

6 years ago
Deals

Adap­ti­m­mune pledges $312M for Noile-Im­mune's T cell boost­ing tech in dri­ve to de­liv­er on TCR promise

6 years ago
Deals

Cadre of gene-edit­ing biotechs ral­ly against al­ter­ing DNA that could af­fect fu­ture gen­er­a­tions

6 years ago

Biotech tar­get­ing rare heart mu­ta­tion with gene ther­a­py scores $11M in Se­ries A haul

6 years ago
Financing
Startups

Plug­ging in the last piece to its gene ther­a­py puz­zle, AskBio ac­quires Scot­tish syn­thet­ic pro­mot­er com­pa­ny

6 years ago
Deals

Ques­tions pile up for No­var­tis as sen­a­tors call on FDA to take ac­tion

6 years ago
FDA+
First page Previous page 50515253545556 Next page Last page
A service from the Financial Times